Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Merck
Baxter
Boehringer Ingelheim
Johnson and Johnson

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Thymosin beta-4

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Thymosin beta-4?

Thymosin beta-4 is an investigational drug.

There have been 9 clinical trials for Thymosin beta-4. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2006.

The most common disease conditions in clinical trials are Keratoconjunctivitis Sicca, Myocardial Infarction, and Dry Eye Syndromes. The leading clinical trial sponsors are RegeneRx Biopharmaceuticals, Inc., sigma-tau i.f.r. S.p.A., and ReGenTree, LLC.

Recent Clinical Trials for Thymosin beta-4
TitleSponsorPhase
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial InfarctionRegeneRx Biopharmaceuticals, Inc.Phase 2
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry EyeORA, Inc.Phase 2
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry EyeReGenTree, LLCPhase 2

See all Thymosin beta-4 clinical trials

Clinical Trial Summary for Thymosin beta-4

Top disease conditions for Thymosin beta-4
Top clinical trial sponsors for Thymosin beta-4

See all Thymosin beta-4 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
McKinsey
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.